GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » Short Interest

Affymax, (FRA:A5Y) Short Interest


View and export this data going back to . Start your Free Trial

What is Affymax, Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Affymax,'s Short Interest

For the Biotechnology subindustry, Affymax,'s Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affymax,'s Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax,'s Short Interest distribution charts can be found below:

* The bar in red indicates where Affymax,'s Short Interest falls into.


Affymax, (FRA:A5Y) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » Short Interest
Comparable Companies
TSXV:APC APOP BOM:532871 ONTX BTHE TSXV:PBS GLPH BRTX AURX PTEO AKAOQ TIKRF NVIV ATMS CAPS HSTC TSXV:COT BOM:542765 TSXV:MFS RSPI
Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Website
http://www.affymax.com
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines